Skip to content

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

Home
- Home
About BR&R
Biosimilar Approval Status
BR&R Product Profiles
- Abrilada
- Amjevita
- Avasola
- Byooviz
- Cyltezo
- Erelzi
- Eticovo
- Fulphila
- Fylnetra
- Hadlima
- Herzuma
- Hulio
- Hyrimoz
- Inflectra
- Kanjinti
- Mvasi
- Nivestym
- Nyvepria
- Ogivri
- Ontruzant
- Releuko
- Renflexis
- Retacrit
- Rezvoglar
- Riabni
- Ruxience
- Semglee
- Trazimera
- Truxima
- Udenyca
- Yusimry
- Zarxio
- Ziextenzo
- Zirabev
Contact Us
The 2023 Biosimilars Market Report

$0.00 0 items

Lupin logo

Stanton Mehr January 16, 2018

Published by Stanton Mehr

View all posts by Stanton Mehr

Published January 16, 2018

Post navigation

Previous Post A Profile on Lesser-Known Player in the Biosimilar Space: Lupin Pharmaceuticals

Leave a Reply Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

SM Health Comm

Search for:

Recent Posts

Advancing Global Harmonization of Biosimilar Evaluations March 27, 2023
Insulin Price Cuts and the Questions for the Biosimilar Market March 24, 2023
Which Ten Medicines Will Be Medicare’s First Drug Price Negotiation Targets? March 16, 2023
Coherus’ Struggling Picture Prior to Udenyca On-Body Injector Approval and Yusimry Launch March 14, 2023
How Much Does Provider Comfort With Biosimilar Prescribing Matter? February 23, 2023
FDA Seeking Help With Biosimilar Development Streamlining Process February 17, 2023
The Inflation Reduction Balancing Act on Rebate Clawbacks February 10, 2023
Sandoz Sends 351(k) BLA to FDA for First Denosumab Biosimilar February 8, 2023
Amgen Launches Amjevita® With Two WAC-Based Pricing Options February 1, 2023
Put Your Money Where Your Mouth Is January 24, 2023

Recent Comments

	Celltrion's Pen… on The Implications of Celltrion’…
	40th Biosimilar Appr… on FDA Approves Fresenius Kabi’s…
	Biogen Announces Sub… on Tocilizumab Biosimilars Approa…
	J&J Slaps Patent… on Ustekinumab Biosimilars Update
	J&J Slaps Patent… on Preliminary Phase 3 Study Data…

Archives

Archives

Meta

Log in
Entries feed
Comments feed
WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

Top Posts & Pages

Insulin Price Cuts and the Questions for the Biosimilar Market
Advancing Global Harmonization of Biosimilar Evaluations
Biosimilar Approval Status
The Evolution of the Biosimilars Market
A Conversation With Ian Henshaw
Which Ten Medicines Will Be Medicare’s First Drug Price Negotiation Targets?
Yusimry
The Inflation Reduction Balancing Act on Rebate Clawbacks
Amgen, Pfizer Now Seeking Adalimumab Interchangeability, but…
Amgen Launches Amjevita® With Two WAC-Based Pricing Options

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

Twitter
LinkedIn

Home
About BR&R
Biosimilar Approval Status
Contact Us
Terms and Conditions

Copyright

Copyright 2013-2023 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.